Gan & Lee Pharmaceuticals (603087.SS) Earnings Analysis
Gan & Lee Pharmaceuticals (603087.SS) next reports earnings on 2026-08-26, consensus EPS 0.77 CNY. Last quarter (2026-04-23) it missed with EPS 0.32 CNY vs 0.57 CNY est (-43.9%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E 38.53.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603087.SS next report earnings?
| Next earnings date | 2026-08-26 |
|---|---|
| Consensus EPS estimate | 0.77 CNY |
| Revenue estimate | 1.31B |
603087.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-23 | 0.32 CNY | 0.57 CNY | -43.9% | Miss |
| 2026-04-22 | 0.54 CNY | 0.45 CNY | +20% | Beat |
| 2025-10-30 | 0.3654 CNY | 0.51 CNY | -28.4% | Miss |
| 2025-03-31 | 0.53 CNY | n/a | n/a | n/a |
| 2024-08-28 | 0.35 CNY | 0.35 CNY | 0% | Beat |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
603087.SS valuation and analyst view
| Trailing P/E | 38.53 |
|---|---|
| Trailing EPS | 1.742 CNY |
| Price / book | 3.31 |
| Dividend yield | 1.50% |
| Market cap | 40.43B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Gan & Lee Pharmaceuticals (603087.SS)'s next earnings date?
Gan & Lee Pharmaceuticals is next scheduled to report on 2026-08-26, with a consensus EPS estimate of 0.77 CNY and revenue estimate of 1.31B.
Did 603087.SS beat earnings last quarter?
In its 2026-04-23 report, 603087.SS posted EPS of 0.32 CNY versus a 0.57 CNY estimate — a miss of 43.9%.
What is 603087.SS's earnings track record?
Over the last 4 reported quarters with consensus data, 603087.SS beat estimates 2 times (50%).
What is 603087.SS's current P/E ratio and EPS?
603087.SS trades at a trailing P/E of 38.53 on trailing EPS of 1.7421253156982128 CNY.
What do analysts rate 603087.SS?
603087.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.